Abstract Phosphodiesterase-5 (PDE-5) inhibitors selectively inhibit PDE-5 enzymes that are
present in various tissues like penile tissue, platelets, vascular, and smooth muscle tissue …

OBJECTIVES: Although the discovery of phosphodiesterases (PDEs) was made soon after
the identification of cyclic adenosine monophosphate nearly half a century ago, their true …

Abstract Phosphodiesterase type-5 inhibitor (PDE5-i) drugs were first marketed in 1998
(sildenafil) for'ondemand'treatment of male erectile dysfunction (ED) of any origin. They …

Three different phosphodiesterase 5 (PDE5) inhibitors are currently available for the
treatment of erectile dysfunction: sildenafil, vardenafil and tadalafil. The differences between …

Abstract The phosphodiesterase-5 inhibitors (PDE5i) sildenafil, vardenafil, and tadalafil are
considered first-line therapy for the treatment of patients with erectile dysfunction (ED). In …

OBJECTIVE: Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is),
addressing critical issues in their current and future use, assessing unanswered questions …

ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate
monophosphate (cGMP) specifically to 5′ GMP. PDE5 inhibitors were a breakthrough …

PDE-5 inhibitors were originally studied in cardiovascular indications but were later
developed and approved for on-demand treatment of erectile dysfunction (ED). A few years …

Since the discovery of sildenafil in 1989 as a highly selective inhibitor of the
phosphodiesterase type-5 (PDE-5) receptor, 2 additional PDE-5 inhibitors, tadalafil and …

Cardiovascular diseases like hypertension, hyperlipidemia, diabetes mellitus and obesity
are the important predictors of erectile dysfunction (ED). Endothelial dysfunction is proposed …